ANSWERS: 1
  • According to an article in this morning's newspaper, the federal court invalidated the patent on Friday,January 28, 2005 for Merck & Co.'s second-largest selling drug for osteoporosis treatment, Fosamax. Under the ruling, the generic competition could begin as soon as early 2008 instead of 2018. The patent had been challenged by generic drugmaker Teva Pharmaceuticals USA Inc. of North Wales, Pa.

Copyright 2023, Wired Ivy, LLC

Answerbag | Terms of Service | Privacy Policy